Seasoned investment banker Jed Cohen has joined Raymond James as a managing director of its healthcare investment banking practice. The strategic hire underscores the firm’s continuing commitment to expanding the sector...
Search results for - Raymond james
Raymond James ups Eupraxia PT on new osteoarthritis data
Raymond James raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $17 (Canadian) from $11, maintaining a “strong buy” rating, after the company reported positive Phase 2b data with EP-104IAR for pain...
Raymond James starts Fusion Pharma at OP; PT $13
Raymond James initiated coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with an “outperform” rating and $13 price target. The stock closed at $4.37 on June 22. Fusion is a precision oncology company that has built a...
Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval
Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...
Raymond James adds 3 senior bankers to healthcare practice
Raymond James Ltd. (CNW Group/Raymond James Ltd.) Raymond James again expanded its healthcare investment banking practice with the addition of three senior bankers. Joining the firm as managing directors are Jeff...
Raymond James ups Quipt Home Medical PT after acquisition
Raymond James raised its price target for Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) to $14 from $10, and reiterated its “outperform” rating after the company acquired Great Elm Healthcare for about $80-million. The...
Raymond James sees catalyst-rich two years ahead for Profound
Raymond James analyst, Rahul Sarugaser, Ph.D., outlined a series of potential catalysts for Profound Medical (NASDAQ:PROF; TSX:PRN), through 2023 and 2024 as it continues to commercialize its TULSA-PRO medical device to...
Raymond James starts POINT Biopharma at OP; PT $10
Raymond James initiated coverage of POINT Biopharma (NASDAQ:PNT) with an “outperform” rating and price target of $10 target. The stock closed at $6.61 on Dec. 13. POINT is a precision oncology company focused on the...
Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO
Analyst Rahul Sarugaser, Ph.D., writes that there is a high likelihood that Profound Medical (NASDAQ:PROF) will receive a category-1 CPT code from the Centers for Medicare and Medical Services when it files an...
Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial
Raymond James raised its price target for Eupraxia Pharmaceuticals (TSXV:EPRX) to $9 (Canadian) from $7 and reiterated its “outperform” rating after the company initiated a Phase 2 clinical trial in eosinophilic...
